UK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. Despite the regular-session pop (+8.63%), the stock is being sold down hard post-market (-13.09%) to ~0.61, right at key support (S1 ~0.611). With bearish longer-term moving averages (SMA200 > SMA20 > SMA5) and no Intellectia buy signals, the setup is not attractive for an impatient buyer who doesn’t want to wait for confirmation. I would avoid buying here; if already holding, this is closer to a sell/avoid-add decision than a buy.
Trend/structure: Bearish overall (SMA200 > SMA20 > SMA5), implying the broader downtrend is still intact. Momentum: MACD histogram is positive (0.00348) and expanding, which hints at a short-term momentum improvement, but it’s not enough to override the bearish moving-average stack. RSI(6) ~51.4 is neutral—no oversold edge. Levels: Pivot 0.676 is overhead; resistance at 0.741 then 0.781. Support is 0.611 (S1) with next support 0.571 (S2). The post-market price ~0.61 is sitting on/just below S1—if it fails to reclaim 0.676 soon, downside risk toward 0.571 is elevated. Probabilistic pattern read: similar-candlestick analysis shows a 50% chance of ~-5.41% next day and ~-5.95% next week, with a possible rebound next month (+13.54%), but near-term skew is negative.
Intellectia Proprietary Trading Signals
MACD turning positive/expanding suggests improving short-term momentum. The pattern-based outlook allows for a potential rebound over the next month (+13.54%). Price is near a defined support zone (around 0.611), which can sometimes trigger technical bounces.
Strong post-market selloff (-13.09%) undermines the regular-session gain and signals weak demand at current levels. The moving-average stack is bearish (SMA200 > SMA20 > SMA5), indicating the dominant trend is still down. Near-term pattern probabilities lean negative (next day/week). No recent news catalysts to justify the volatility or support a sustained move. No notable hedge fund/insider trend signals; Congress trading data: none.
Financial snapshot unavailable (data error: "list index out of range"), so latest quarter/season growth trends cannot be assessed from the provided data.
No analyst rating/price-target change data provided. With no visible Wall Street updates here, the practical takeaway is limited external sponsorship/coverage signal, so the decision should lean more heavily on price action and technicals—which are currently not supportive of an impatient buy.
